Spin-out success stories
Maple Glass, a Monash startup company, is developing affordable glass 3D printing technology with the use of glass waste and recycling processes that will expand the reuse of glass in industrial applications.
Septerna Inc. was launched with US$100 million in financing to discover and advance novel small molecules medicines that target G-proten-coupled receptors (GPCRs).
Monash researchers have invented a method that uses an electrochemical process to produce ammonia by reducing nitrogen extracted from the air and combining it with hydrogen extracted from water, with power provided by renewable electricity.
Pio Therapeutics (Pio Tx)
A world-class team at Pio Tx is developing novel, innovative and targeted medicines that improve outcomes for cancer patients. Pio Tx focuses on medicines that increase endogenous anti-tumour immunity.
RAGE Biotech is developing novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease.
Monash researchers have collaborated on a technology to treat fibrosis – a condition associated with many chronic diseases, where tissue damage leads to scarring and loss of organ function.
AskPCOS is the first evidence-based polycystic ovary syndrome app. Through research and collaboration of leading global PCOS experts, the app is helping women to get a clear diagnosis and to access key information.
Additive Assurance is a Monash spin-out company created to commercialise a novel in-situ monitoring tool for metal 3D printing.
KASPR Datahaus provides real-time information about the world’s internet infrastructure, by collecting over 3.8 billion measurements from over 400 million geo-referenced internet end-points every day.
Cincera Therapeutics Pty Ltd
Drug discovery research at Monash has resulted in a spin-out company developing therapies for metabolic syndrome and type-2 diabetes-related diseases.
2D Water Pty Ltd
In response to the increasing scarcity of fresh water, Monash researchers have developed new membranes for desalination and water purification, with significantly improved functionality and energy efficiency.
The MoodMission smartphone app is designed to be used by anyone, whether they have a clinically significant anxiety or mood disorder, or just want to find ways of coping with day-to-day feelings of anxiousness or low moods.
Mogrify is developing novel technologies to direct cellular programming and to identify optimal culture conditions.
Monash researchers have invented a cost-effective and scalable way to split graphite into microscopic sheets and introduce ions or molecules between the layers to form a stable graphene gel that can then be converted into a number of useful products.
Aravax – Peanut allergy
Monash researchers working in conjunction with Alfred Health have developed a specific peptide immunotherapy as a safe treatment for peanut allergy.
Amaero International (ASX:3DA)
Amaero manufactures large format complex metal components in Melbourne, Adelaide and California and is well positioned to provide 3D manufacturing services to a global customer base.
4D Medical (ASX:4DX)
Four-dimensional x-ray imaging technology developed by Monash Engineering is providing state-of-the-art, non-invasive ways of understanding real time lung motion and airflow.
AquaHydrex water splitting technologies are the culmination of years of research that's now fundamentally redesigned water electrolysis to create an ideal platform for producing Green Hydrogen.
Low FODMAP diet app
Launched in response to an increasing number of requests about the FODMAP content of foods, the Monash University Low FODMAP diet smartphone application helps users manage symptoms of IBS by restricting foods that are high in certain short-chain-carbohydrates.
By using artificial intelligence, Opturion is revolutionising the way decisions are made in transport, logistics, manufacturing and maintenance.
Monash IVF (ASX:MVF)
The Monash In Vitro Fertilisation research program resulted in the first human IVF pregnancy in 1973. Monash IVF have continued to achieve many Australian and world firsts, enabling new technologies to be delivered to patients as soon as they're available.
Acrux – Drug delivery (ASX:ACR)
Acrux is a spin-off biotech company from Monash, recognised for its innovative technology in administering drugs through the skin.